Use of a gene expression signature to identify trimetazidine for repurposing to treat bipolar depression - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Bipolar Disorders Année : 2023

Use of a gene expression signature to identify trimetazidine for repurposing to treat bipolar depression

Trang Truong
Bruna Panizzutti

Résumé

Objectives The aim of this study was to repurpose a drug for the treatment of bipolar depression. Methods A gene expression signature representing the overall transcriptomic effects of a cocktail of drugs widely prescribed to treat bipolar disorder was generated using human neuronal-like (NT2-N) cells. A compound library of 960 approved, off-patent drugs were then screened to identify those drugs that affect transcription most similarly to the effects of the bipolar depression drug cocktail. For mechanistic studies, peripheral blood mononuclear cells were obtained from a healthy subject and reprogrammed into induced pluripotent stem cells, which were then differentiated into co-cultured neurons and astrocytes. Efficacy studies were conducted in two animal models of depressive-like behaviours (Flinders Sensitive Line rats and social isolation with chronic restraint stress rats). Results The screen identified trimetazidine as a potential drug for repurposing. Trimetazidine alters metabolic processes to increase ATP production, which is thought to be deficient in bipolar depression. We showed that trimetazidine increased mitochondrial respiration in cultured human neuronal-like cells. Transcriptomic analysis in induced pluripotent stem cell-derived neuron/astrocyte co-cultures suggested additional mechanisms of action via the focal adhesion and MAPK signalling pathways. In two different rodent models of depressive-like behaviours, trimetazidine exhibited antidepressant-like activity with reduced anhedonia and reduced immobility in the forced swim test. Conclusion Collectively our data support the repurposing of trimetazidine for the treatment of bipolar depression.
Fichier principal
Vignette du fichier
Bipolar Disorders - 2023 - Bortolasci.pdf (1.7 Mo) Télécharger le fichier
Origine : Publication financée par une institution
Licence : CC BY - Paternité

Dates et versions

inserm-04060062 , version 1 (05-04-2023)

Identifiants

Citer

Chiara Bortolasci, Srisaiyini Kidnapillai, Briana Spolding, Trang Truong, Timothy Connor, et al.. Use of a gene expression signature to identify trimetazidine for repurposing to treat bipolar depression. Bipolar Disorders, 2023, Online ahead of print. ⟨10.1111/bdi.13319⟩. ⟨inserm-04060062⟩

Collections

INSERM IMRB UPEC
10 Consultations
39 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More